2011 - IPITA - Prague


This page contains exclusive content for the member of the following sections: TTS, IPITA. Log in to view.

Parallel session 9 – Open oral presentations Topic: Pancreas transplantation: Long-term function and rejection

9.7 - Long-term outcomes of solitary pancreas transplantation: Do surveillance pancreas biopsies level the playing field?

Presenter: A., Farney, Winston-Salem, USA
Authors: A. Farney, J. Rogers, S. Al-geizawi, S. Iskandar, R. Stratta


Long-term outcomes of solitary pancreas transplantation: Do surveillance pancreas biopsies level the playing field?

A. Farney, J. Rogers, S. Al-geizawi, S. Iskandar, R. Stratta
Wake Forest Univ School of Medicine, General Surgery, Winston-Salem, NC, USA

We sought to determine the impact of surveillance pancreas biopsies (SPbxs) on long-term outcomes of solitary pancreas transplants (SPT).

Methods: Single center retrospective analysis of all SPT and simultaneous kidney-PTs (SKPT) performed with antibody induction, FK, MMF, and steroids. Following SPT, SPbxs were performed at 3 week intervals until there were 2 consecutive normal biopsies (bxs). Acute rejection (AR) grade I bxs were treated with steroids ± antibody with follow-up (f/u) bxs every 3 weeks until inflammation resolved. Clinical bxs were prompted by biochemical parameters.

Results: 35 SPT (32 PAK, 3 PA) and 122 SKPTs were performed with a mean f/u of 5±2.5 years. 26 (74%) SPT underwent at least 1 SPbx (mean 2±0.9 bxs/graft). 9 pancreas grafts (PG) were not bx'd due to early thrombosis, infection, or other reasons. Of the 26 PG bx'd, 12 (34%) had some inflammation (>grade indeterminate) detected and 9 (26%) had at least 1 bx with AR>grade I. 8 of 9 (89%) AR>grade I episodes were subclinical. Demographics for SPT vs SKPT were mostly comparable; however, the SPT group had fewer HLA mismatches (SPT 3±1.3, SKPT 4.5±1.3, P<0.001), younger donors (SPT 22±7.6, SKPT 28±12 yrs, P=0.004), and fewer black recipients (SPT 5.7%, SKPT 20%, P=0.04).

Pancreas Graft Survival

Patient Survival

1 yr

3 yrs

5 yrs

1 yr

3 yrs

5 yrs

SPT

92%

83%

75%

100%

100%

95%

SKPT

87%

80%

74%

97%

94%

93%

P=0.71

P=0.29


Causes of PG loss were comparable between SPT and SKPT. Cumulative clinical AR rates were similar between groups (SPT 26%, SKPT 29%, P=0.7).

Conclusions: There is a significant incidence of early subclinical AR in SPT. Antibody induction, HLA matching, careful PG selection, and SPbxs in SPT with treatment of early subclinical AR episodes yield excellent long-term PG survival rates that are equivalent to those in SKPT.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada